Trial studying safety and effects for Fibrotic Interstitial Lungs Diseases
Official title Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.
ClinicalTrials.gov ID: NCT07466420
What this study is testing
What is Quercetin?
an investigational oral supplement being studied as a potential treatment for fibrotic interstitial lung diseases (including IPF) is designed to act as an antioxidant and senolytic agent that may reduce cellular senescence and inflammation
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if quercetin can change cellular aging markers, inflammation proteins, and lung function in these patients.
- Who it's for
- Adults diagnosed with idiopathic pulmonary fibrosis or other fibrotic interstitial lung diseases.
- What's involved
- Participants will take 500 mg of quercetin each day for two 12‑week periods, with an 8‑week break in between, while continuing their usual care. They will have regular clinic visits for lung tests and questionnaires.
- Time commitment
- The trial lasts about 32 weeks total, with visits spread across the two treatment periods and the washout phase.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients with an established diagnosis of IPF and Fibrotic ILD and will be eligible to participate in the study.
- The use of the approved standard of care antifibrotic therapy, either nintedanib or pirfenidone, and immunosuppressive therapy will be allowed as...
You likely can't join if
- people with a result of FeNO\>25 ppb will be excluded from the study to ensure that no other pulmonary diseases, such as asthma, are present.
- Patients who do not initiate quercetin within the first week after their baseline visit.
The study team makes the final eligibility decision.
Where it is enrolling
- Heraklion, Crete, Greece
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Heraklion, Crete, Greece. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.